about
Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profilingReverse Genetics Approaches for the Development of Influenza VaccinesMutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibilityA consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza virusesInfluenza pandemic preparedness action plan for the United States: 2002 update.System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test.Strategies to achieve the healthy people 2020 annual influenza vaccine coverage goal for health-care personnel: recommendations from the national vaccine advisory committeeLong-term care facilities: a cornucopia of viral pathogens.Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis.Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virusEfficacy and effectiveness of maternal influenza vaccination during pregnancy: a review of the evidence.Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus.
P2860
Q21131780-CA22FD6A-DA97-461D-86C3-BA872135957AQ28076140-139BEC14-3BBD-478D-96E2-C91D7A3D16F9Q28385604-5EACE7A9-109C-40E9-851B-8B4C1D165FF9Q30228657-470F398E-E11D-49C5-A7FA-6DBF75171836Q30233490-2478858E-A03B-40D9-AC14-14C0479AEC75Q30364552-CDDCD810-BC9D-4027-96D7-EE66C22941B0Q30415584-AFBFBD5E-0724-41E8-BD2A-A4CF8A67C54CQ33874903-60785F5F-A568-4267-8D00-0B70C0CC0AC0Q33979363-94D23AB2-02DD-4E9D-A56B-0F14A0E019B2Q36057500-F5696F8A-2C4A-4E42-8554-ABEECBAEAF72Q36900058-B391D307-B31A-4503-B2A0-64AD776C4F75Q38165876-1ED98B8A-3C4E-46FF-9601-65F8651BA9C1Q42096994-0633401C-37B1-47AA-B993-DBE2E29EE827Q46749615-CB2789ED-8A10-4A8D-B3E7-EB6EAEBA793E
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Improvement of inactivated influenza virus vaccines.
@ast
Improvement of inactivated influenza virus vaccines.
@en
type
label
Improvement of inactivated influenza virus vaccines.
@ast
Improvement of inactivated influenza virus vaccines.
@en
prefLabel
Improvement of inactivated influenza virus vaccines.
@ast
Improvement of inactivated influenza virus vaccines.
@en
P2093
P356
P1476
Improvement of inactivated influenza virus vaccines.
@en
P2093
P304
P356
10.1086/514173
P407
P478
176 Suppl 1
P577
1997-08-01T00:00:00Z